REPL Replimune Group, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
11:37
May 29
May 29
Author re-enters $REPL long, citing a shift in FDA direction after key personnel exits.
REPL
Replimune Group, Inc.
Long
1ST
—
—
15:46
Apr 13
Apr 13
CNBC
Replimune's drug has strong efficacy and support.
The FDA rejection of Replimune's melanoma drug was unfair because the drug has strong efficacy data with a 34% remission rate and durable responses, it resensitizes patients to anti-PD-1 therapy, and has broad support from oncologists and patient advocacy groups, indicating that the drug should be approved and the company has promising prospects.
REPL
Replimune Group, Inc.
Long
1ST
—
—
About REPL Investor Commentary
Across the available history and selected sources, Buzzberg tracks REPL (Replimune Group, Inc.) across 7 sources: 2 bullish vs 0 bearish calls from 7 authors. Historical directional balance: 14% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 14 total trade ideas tracked. Latest voices: seedy19tron, Philip Astley-Sparke.